Day 3 Embryo Biopsy Versus Blastocyst Biopsy in PGS Cases (VINCI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01950104|
Recruitment Status : Withdrawn (No started, lack of funding)
First Posted : September 25, 2013
Last Update Posted : March 6, 2020
Preimplantation genetic diagnosis (PGS) is a technique that allow us to improve the results of assisted reproduction techniques through the selection of embryos free of chromosomal abnormalities.
At present, it has not been proved that the usage of PGS really improves the live birth rate in IVF cycles. However, it has been stated that the reason of not having better results when using PGS is that the methodology applied is not adequate.
Several authors propose that the optimal methodology for PGS includes the application of comparative genomic hybridization (CGH) arrays for genetic testing and carrying out embryo biopsy at the blastocyst stage. Nevertheless, most IVF centres still applies the day 3 embryo biopsy as a daily routine. Despite this fact, there is a gradual transition towards the usage of blastocyst-stage biopsy instead of day 3 biopsy.
The purpose of this clinical study is analysing the results of the IVF cycles with embryo biopsy for PGS. Live birth rates and other parameters as the pregnancy and implantation rates together with embryo quality will be analysed and compared between two groups of patients undergoing IVF cycles with PGS. In one group the biopsy will be applied in day 3 of the embryo development, while in the other group the embryo biopsy will be fulfilled at the blastocyst stage.
|Condition or disease||Intervention/treatment||Phase|
|Infertility Embryo Biopsy||Other: Day 3 embryo biopsy Other: Blastocyst biopsy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparative Study Between Day 3 Embryo Biopsy and Blastocyst Biopsy in Preimplantation Genetic Screening Cases|
|Actual Study Start Date :||August 2015|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||August 2015|
Active Comparator: Day 3 embryo biopsy
Embryo biopsy is applied at day 3 of the embryo development
Other: Day 3 embryo biopsy
Embryo biopsy is applied at day 3 of the embryo development.
Experimental: Blastocyst biopsy
Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
Other: Blastocyst biopsy
Embryo biopsy is applied at the blastocyst stage of the embryo development
- Live birth rate [ Time Frame: 20 months ]
- Fertilization rate [ Time Frame: 1 year ]
- Embryo quality [ Time Frame: 1 year ]Day 3 embryo quality
- Implantation rate [ Time Frame: 1 year ]
- Pregnancy rate [ Time Frame: 20 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01950104
|Seville, Spain, 41006|